SOURCE: Aureon Laboratories

March 16, 2006 08:00 ET

Aureon Laboratories Announces New Vice President of Pathology

YONKERS, NY -- (MARKET WIRE) -- March 16, 2006 -- Aureon Laboratories announced today that Dr. Ricardo Mesa-Tejada has joined as Vice President of Pathology and Medical Director. Dr. Mesa-Tejada has extensive experience in anatomic pathology having served on the faculty at Columbia University where he holds a part-time appointment as Associate Clinical Professor of Pathology, as well as leadership positions with Quest Diagnostics and MetPath/Corning Clinical Laboratories. Since leaving Quest he has served as a consultant to specialty pathology laboratories, biotechnology companies and as a biomedical advisor to Thieme Associates, an investment group. Dr. Mesa-Tejada has served on a number of committees and review panels (NIH/NCI, NCCLS, among others), has several patents and has published extensively.

Dr. Mesa-Tejada will be responsible for expanding our team of diagnostic pathologists with expertise in the various disciplines involved in Systems Pathology including immunohistochemistry, molecular biology, and bioinformatics. In addition he will foster interdisciplinary interactions between pathologists, scientists and technologists at all levels, both in production and R&D, to insure the highest quality while setting priorities for next-generation predictive tests.

"I am delighted and honored to have been asked to join Aureon, particularly at the time of the release of Prostate Px™, the first predictive clinical test for prostate cancer developed with Aureon's unique Systems Pathology platform," said Dr. Mesa-Tejada. "I look forward to working with this expert team to extend the application of Systems Pathology to other malignancies and diseases, with the ultimate goal of making a major impact on patient care."

"The appointment of Dr Mesa-Tejada follows an extensive nation-wide search. We look forward to the many ways that he will help Aureon Laboratories as we develop the next generation of personalized predictive tests in oncology," stated Vijay Aggarwal, Ph.D., Aureon's CEO and President.

About Aureon Laboratories

Aureon Laboratories' mission is to enable personalized patient care through predictive pathology. Aureon has developed a high throughput Systems Pathology technology platform to predict individual clinical outcomes through the interrogation of tissue. The platform generates and analyzes an integrated, digital view of clinical findings, tissue micro-anatomy and tissue molecular pathology to determine which combination of features predicts specified individual clinical outcomes. Allied with major cancer centers, Aureon operates a CLIA-certified laboratory that provides predictive pathology services to the practicing physician. For more information about Aureon, go to www.aureon.com or call 1-888-SYS-PATH.

NOTE: Prostate Px is a trademark of Aureon Laboratories, Inc.

Contact Information

  • Contact:
    Jason Alter, Ph.D.
    Director of Marketing
    Aureon Laboratories
    Phone: 914-377-4036
    Fax: 914-377-4001
    Email Contact